A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS. 2006;96:223–268. doi:10.1007/3-7643-7378-4_10
   PubMedGoogle Scholar
• Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653–660. doi:10.1038/nm0603-653
   PubMed Web of Science ®Google Scholar
• Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333(26):1757–1763.
   PubMed Web of Science ®Google Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. PMID: 30231931; PMCID: PMC6146601. doi:10.1186/s13045-018-0664-7
   PubMed Web of Science ®Google Scholar
• Kerbel RS. A decade of experience in developing preclinical models of advanced- or early-stage spontaneous metastasis to study antiangiogenic drugs, metronomic chemotherapy, and the tumor microenvironment. Cancer J. 2015;21(4):274–283. PMID: 26222079. doi:10.1097/PPO.0000000000000134
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12(1):47. PMID: 31046803; PMCID: PMC6498593. doi:10.1186/s13045-019-0736-3
   PubMed Web of Science ®Google Scholar
• Desai J, Deva S, Lee JS, et al. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. J Immunother Cancer. 2020;8(1):e000453. PMID: 32540858; PMCID: PMC7295442. doi:10.1136/jitc-2019-000453
   PubMed Web of Science ®Google Scholar
• Ghahremanloo A, Soltani A, Modaresi SMS, Hashemy SI. Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol. 2019;42(5):609–626. PMID: 31201647. doi:10.1007/s13402-019-00456-w
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48(3):434–452. PMID: 29562194; PMCID: PMC7116507. doi:10.1016/j.immuni.2018.03.014
   PubMed Web of Science ®Google Scholar
• Fucà G, De Braud F, Di Nicola M. Immunotherapy-based combinations: an update. Curr Opin Oncol. 2018;30(5):345–351. PMID: 29994900. doi:10.1097/CCO.0000000000000466
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. PMID: 30925919; PMCID: PMC6441150. doi:10.1186/s12943-019-0974-6
   PubMed Web of Science ®Google Scholar
• Chu T, Zhang W, Zhang B, et al. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study. Transl Lung Cancer Res. 2022;11(7):1394–1404. PMID: 35958322; PMCID: PMC9359953. doi:10.21037/tlcr-22-438
   PubMed Web of Science ®Google Scholar
• Su Y, Luo B, Lu Y, et al. Anlotinib Induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin Cancer Res. 2022;28(4):793–809. PMID: 34844980; PMCID: PMC9377760. doi:10.1158/1078-0432.CCR-21-2241
   PubMed Web of Science ®Google Scholar
• Zheng W, Sun G, Li Z, et al. The effect of anlotinib combined with anti-PD-1 in the Treatment of gastric cancer. Front Surg. 2022;9:895982. PMID: 35495754; PMCID: PMC9039330. doi:10.3389/fsurg.2022.895982
   PubMed Web of Science ®Google Scholar
• Manegold C, Dingemans AC, Gray JE, et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. Cancer Immunol Res. 2019;7(4):630–643. PMID: 30755403. doi:10.1158/2326-6066.CIR-17-0640
   PubMed Web of Science ®Google Scholar
• Wang Q, Gao J, Di W, Wu X. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models. Cancer Immunol Immunother. 2020;69(9):1781–1799. PMID: 32347357. doi:10.1007/s00262-020-02576-x
   PubMed Web of Science ®Google Scholar
• Allen E, Jabouille A, Rivera LB, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385):eaak9679. PMID: 28404866; PMCID: PMC5554432. doi:10.1126/scitranslmed.aak9679
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012;32(12):1095–1111. PMID: 23208836; PMCID: PMC3555403. doi:10.1002/phar.1147
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654–661. PMID: 29438373; PMCID: PMC5846072. doi:10.1038/bjc.2017.478
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. PMID: 30098152; PMCID: PMC6248083. doi:10.1001/jamaoncol.2018.3039
   PubMed Web of Science ®Google Scholar
• Shi J, Cheng Y, Wang Q, et al. Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized Phase 2 study (ALTER1202). Front Med. 2022;16(5):766–772. PMID: 35844026. doi:10.1007/s11684-021-0916-8
   PubMed Web of Science ®Google Scholar
• Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171–6180. PMID: 20631075; PMCID: PMC2912959. doi:10.1158/0008-5472.CAN-10-0153
   PubMed Web of Science ®Google Scholar
• Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013;19(2):393–403. PMID: 23204132; PMCID: PMC4120472. doi:10.1158/1078-0432.CCR-12-1626
   PubMed Web of Science ®Google Scholar
• Georganaki M, Van Hooren L, Dimberg A. Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol. 2018;9:3081. PMID: 30627131; PMCID: PMC6309238. doi:10.3389/fimmu.2018.03081
   PubMed Web of Science ®Google Scholar
• Xu Q, Wang J, Sun Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. J Clin Oncol. 2022;40(16):1795–1805. PMID: 35192397; PMCID: PMC9148684. doi:10.1200/JCO.21.02091
   PubMed Web of Science ®Google Scholar
• Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37(17):1470–1478. PMID: 30943124. doi:10.1200/JCO.18.01265
   PubMed Web of Science ®Google Scholar
• Hao YY, Qiao YP, Cheng JD. Clinical activity and safety of anlotinib combined with PD-1 blockades for patients with previously treated small cell lung cancer. Int J Gen Med. 2021;14:10483–10493. PMID: 35002304; PMCID: PMC8722563. doi:10.2147/IJGM.S337316
   PubMed Web of Science ®Google Scholar
• Chen Q, Li Y, Zhang W, Wang C, Yang S, Guo Q. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study. J Cancer Res Clin Oncol. 2022;148(2):401–408. PMID: 34797416; PMCID: PMC8800903. doi:10.1007/s00432-021-03858-2
   PubMed Web of Science ®Google Scholar
• Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer. Cancer Med. 2023;12(5):5372–5383. PMID: 36250532; PMCID: PMC10028028. doi:10.1002/cam4.5360
   PubMed Web of Science ®Google Scholar
• Yuan M, Zhu Z, Mao W, et al. Anlotinib combined with anti-PD-1 antibodies therapy in patients with advanced refractory solid tumors: a single-center, observational, prospective study. Front Oncol. 2021;7;11:683502. PMID: 34692475; PMCID: PMC8529018. doi:10.3389/fonc.2021.683502
   Web of Science ®Google Scholar
• Wallis CJD, Lawson K, Butaney M, et al. Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. Jpn J Clin Oncol. 2020;50(7):800–809. PMID: 32083295. doi:10.1093/jjco/hyaa021
   PubMed Web of Science ®Google Scholar
• Liu X, Guo CY, Tou FF, et al. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: a systematic review and meta-analysis. Int J Cancer. 2020;147(1):116–127. PMID: 31633798. doi:10.1002/ijc.32744
   PubMed Web of Science ®Google Scholar